Approaches for discovery of small-molecular antivirals targeting to influenza A virus PB2 subunit

Drug Discov Today. 2022 Jun;27(6):1545-1553. doi: 10.1016/j.drudis.2022.02.024. Epub 2022 Mar 2.

Abstract

Influenza is an acute respiratory infectious disease caused by influenza virus, leading to huge morbidity and mortality in humans worldwide. Despite the availability of antivirals in the clinic, the emergence of resistant strains calls for antivirals with novel mechanisms of action. The PB2 subunit of the influenza A virus polymerase is a promising target because of its vital role in the 'cap-snatching' mechanism. In this review, we summarize the technologies and medicinal chemistry strategies for hit identification, hit-to-lead and lead-to-candidate optimization, and current challenges in PB2 inhibitor development, as well as offering insights for the fight against drug resistance.

Keywords: Cap-snatching mechanism; Drug discovery; Influenza virus; Medicinal chemistry strategies; PB2 subunit.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / chemistry
  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use
  • Humans
  • Influenza A virus*
  • Influenza, Human* / drug therapy
  • RNA-Dependent RNA Polymerase
  • Viral Proteins

Substances

  • Antiviral Agents
  • Viral Proteins
  • RNA-Dependent RNA Polymerase